SRZN Stock Summary and Trading Ideas (Surrozen | NASDAQ:SRZN)

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).

Surrozen trades on the NASDAQ stock market under the symbol SRZN.

As of November 13, 2026, SRZN stock price declined to $31.54 with 29,825 million shares trading.

SRZN has a beta of 1.68, meaning it tends to be more sensitive to market movements. SRZN has a correlation of 0.05 to the broad based SPY ETF.

SRZN has a market cap of $370.71 million. This is considered a Small Cap stock.

Last quarter Surrozen reported $0 in Revenue and -$11.02 earnings per share. This fell short of revenue expectation by $-380,000 and missed earnings estimates by -$9.70.

In the last 3 years, SRZN traded as high as $37.83 and as low as $5.10.

The top ETF exchange traded funds that SRZN belongs to (by Net Assets): VTI, IWM, JSMD, VXF, IWO.

SRZN has outperformed the market in the last year with a price return of +143.7% while the SPY ETF gained +10.9%. SRZN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.4% and +7.1%, respectively, while the SPY returned -2.6% and -2.4%, respectively.

SRZN support price is $29.96 and resistance is $33.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRZN shares will trade within this expected range on the day.